Entelos, Inc. Patent applications |
Patent application number | Title | Published |
20110275527 | Predictive Toxicology for Biological Systems - Methods and apparatus to identify a potential toxicity of a therapy in a biological system are described. In one embodiment, a method uses a computer model that represents a set of biological processes of the biological system. The method includes executing the computer model to identify a first set of biological processes contributing to the occurrence of a toxic state of the biological system. The method also includes identifying a set of biological assays based on the first set of biological processes and testing the therapy in the set of biological assays to identify a second set of biological processes modified by the therapy. The method further includes identifying the potential toxicity of the therapy based on the second set of biological processes. | 11-10-2011 |
20100324874 | Simulating patient-specific outcomes - The invention encompasses systems, methods, and apparatus for predicting and monitoring an individual's response to a therapeutic regimen. The invention includes multiple virtual patients, an associating subsystem operable to associate the subject with one or more of the virtual patients, and a simulation engine operable to apply one or more experimental protocols to the one or more virtual patients identified with the subject to generate a set of outputs. The set of outputs can represent therapeutic efficacy, identify biomarkers for monitoring therapeutic efficacy, or merely report the status of the biological system as it represents a particular individual | 12-23-2010 |
20100120050 | Biomarkers For Assessing Altherosclerotic Potential - The invention also provides methods, apparatuses and reagents useful for predicting future atherosclerosis based on expression levels of genes selected from the set of 68 genes with differential expression in response to pioglitazone and rosiglitazone. The invention also discloses reagent sets and biomarkers for predicting progression of atherosclerosis induced by anti-diabetic therapy in a subject. In one particular embodiment the invention provides a method for predict whether a compound will induce atherosclerosis using gene expression data from sub-acute treatments. | 05-13-2010 |
20090150134 | Simulating Patient-Specific Outcomes - The invention encompasses systems, methods, and apparatus for predicting clinical outcomes and monitoring an individual's response to a therapeutic regimen. The invention further encompasses methods for predicting cardiovascular risk based a genetic marker status and methods for modifying a computer to reflect genetic data and for incorporating genetic markers into a virtual population. | 06-11-2009 |
20090132219 | Apparatus and Method for Validating a Computer Model - An apparatus and method for validating a computer model is described. In one embodiment, a computer-readable medium comprises instructions to associate a set of configurations of a computer model with a stimulus-response test, each configuration of the set of configurations representing a different model scenario, the stimulus-response test defining a modification to each configuration of the set of configurations. The computer-readable medium also comprises instructions to apply the stimulus-response test to the set of configurations to produce a simulated response for each configuration of the set of configurations and instructions to compare the simulated responses for the set of configurations with an expected response to the stimulus-response test. | 05-21-2009 |
20080213786 | Treatment of rheumatoid arthritis with galectin-3 antagonists - The invention encompasses a novel method of treating an inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases, such as rheumatoid arthritis, and their clinical symptoms. The inventors have made the discovery that the activity of galectin-3, a β-galactoside-binding lectin known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of galectin-3. | 09-04-2008 |